RARE DISEASE
CLN6 disease
CLN6 disease
CLN6 disease
Synonyms: Neuronal ceroid cipofuscinosis type 6, vLINCL
Synonyms: Neuronal ceroid cipofuscinosis type 6, vLINCL
Synonyms: Neuronal ceroid cipofuscinosis type 6, vLINCL
Drug discovery
1
drug
With orphan designation
Overview
CLN6 disease is a rare autosomal recessive neuronal ceroid lipofuscinosis (NCL) marked by progressive neurodegeneration due to CLN6 mutations. Childhood-onset forms (18 months–8 years) feature developmental regression, seizures, ataxia, and vision loss, with rapid functional decline and death typically by adolescence. Adult-onset cases (>30 years) manifest with myoclonus, cognitive decline, and epilepsy, often without vision impairment, and survival ≤10 years post-diagnosis. Pathologically, lysosomal storage accumulation drives neuronal death [1][2][9].
Therapies
Symptomatic management: Antiseizure medications (lamotrigine, levetiracetam), spasticity control (baclofen), and multidisciplinary palliative care [5][8].
Emerging options: Intrathecal AAV9-mediated gene therapy (preclinical efficacy in restoring CLN6 expression, reducing neurodegeneration) [7][10].
Categories: rare genetic diseases, rare inborn errors of metabolism, rare neurological diseases
Research Papers
66 drug discovery papers related to CLN6 disease, with 3 first-in-class and 1 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:
66 drug discovery papers related to CLN6 disease, with 3 first-in-class and 1 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:
2026-04-28 | PPARα and RXRα in the regulation of neuronal ceroid lipofuscinosis genes: implications for Batten disease therapy
Abstract Neuronal ceroid lipofuscinosis or Batten disease comprises a category of autosomal recessive neurodegenerative disorders that primarily affect children. Mutations in different genes lead to different forms of neuronal ceroid lipofuscinoses (CLN1-14). At present, there is no established therapy to cure most of the neuronal ceroid lipofuscinoses and the treatments are symptomatic. Enzyme replacement therapy, gene therapy, stem cell transplantation, and pharmacological chaperone therapy are being tested in different animal models and human patients. Peroxisome proliferator-activated receptor alpha (PPARα) is a member of the nuclear hormone receptor superfamily, which along with its transcription partner retinoid X receptor alpha (RXRα) regulates the expression of their target genes. This review highlights the potential role of PPARα and RXRα in the regulation of CLN genes. Here, using the MatInspector program of the Genomatix software, we performed promoter analyses of all CLN genes and observed that most of the CLN genes harbor one or more potential binding sites for PPAR and RXR in their promoter region. We further grouped them according to a binding prediction of the transcription factors to indicate high affinity binding of PPAR to CLN2 , CLN3 , CLN4 , CLN5, CLN7 , CLN10 , CLN11 , CLN12 , and CLN14 . On the other hand, we observed high affinity binding of RXR to CLN1 , CLN3 , CLN6 , CLN7 , CLN8 , CLN10 , and CLN13 . Since PPARα and RXRα have been demonstrated to control the transcription of CLN2 gene, our current promoter analysis findings highlight a possible treatment strategy for neuronal ceroid lipofuscinoses using agonists of PPARα and RXRα.
2026-03-14 | A Flupirtine Benzyl Carbamate Improves Neurocognitive Deficits and Molecular Pathology in the Cln6nclf Mouse.
Neuronal ceroid lipofuscinosis type 6 (CLN6) is a fatal, autosomal recessive neurodegenerative disorder characterized by cognitive/motor impairment, vision loss, as well as neuronal loss and gliosis in the brain, and premature death. Onset typically occurs in childhood. No approved pharmacological treatments exist that halt or reverse disease progression. A novel flupirtine benzyl carbamate was orally administered to male and female Cln6nclf mice from 4 to 28 weeks of age to evaluate its neuroprotective and antispastic effects. Drug treatment produced significant, sex-dependent phenotypic improvements. Treated mice of both sexes exhibited reduced hindlimb spasticity, but only treated males demonstrated diminution in locomotor hyperactivity and recovery of visuospatial performance. In the brains of male and female Cln6nclf mice, flupirtine benzyl carbamate significantly decreased astrocytosis, microgliosis and mitochondrial ATP synthase subunit C (SCMAS) accumulation, increased neuronal marker expression and reduced the number of TUNEL-positive cells. The treatment failed to rescue photoreceptor loss or clear retinal SCMAS storage. These outcomes result in distinct sex-specific differences in neuronal vulnerability and drug responsiveness. Overall, these findings demonstrate that flupirtine benzyl carbamate diminishes key motor, visual and pathological deficits in CLN6 disease, highlighting its promise as a potential disease-modifying therapy for CLN6 in humans despite sex-specific differences.
2025-10-30 | Phenotype, EEG, neuroimaging and Genetic profile of Progressive Myoclonic Epilepsy in Bangladesh: An observational study
Background: Progressive myoclonic epilepsy (PME) is an epilepsy syndrome characterized by myoclonus, cognitive deficit and ataxia. Common PMEs are Unverricht–Lundborg disease, myoclonic epilepsy with ragged-red fiber (MERRF) syndrome, Lafora body disease, neuronal ceroid lipofuscinoses, and sialidases. This study was conducted to obtain baseline information on PME in terms of phenotype, EEG, MRI of the brain, and overall genetic profile. Methodology: This retrospective observational study was conducted in the Department of Pediatric Neurology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh. The duration of the study was from January 2020 to December 2023. Children diagnosed as PME on the basis of phenotype, EEG, imaging and genotype were included in this study. The genetic diagnosis was done by next-generation sequencing. Result: A total of 11 patients were analyzed in this study. The age of onset ranges from 6 months to 5 years. Consanguinity of the parents was present in 8 cases; one patient had a positive family history of a similar type of illness. The key clinical features were seizure, ataxia, neuroregression, visual impairment, dystonia etc. EEG features showed focal epileptic discharges (6), generalized discharges (5), with progressive deterioration of background in most of the cases. In MRI, 8 out of 11 patients had cerebello-cerebral atrophy. In all cases, next-generation sequencing was done; of them, three cases had KCTD7 gene mutation, three had CLN6 gene mutation causing Neuronal ceroid lipofuscinosis, another three had TPP1 gene mutation and the remaining two had MFSD8(-) gene mutation. Conclusion: This study will highlight the pattern of genotype and phenotype of children with PME in Bangladesh. J Bangladesh Coll Phys Surg 2025; 43: 269-276
2026-04-28 | PPARα and RXRα in the regulation of neuronal ceroid lipofuscinosis genes: implications for Batten disease therapy
Abstract Neuronal ceroid lipofuscinosis or Batten disease comprises a category of autosomal recessive neurodegenerative disorders that primarily affect children. Mutations in different genes lead to different forms of neuronal ceroid lipofuscinoses (CLN1-14). At present, there is no established therapy to cure most of the neuronal ceroid lipofuscinoses and the treatments are symptomatic. Enzyme replacement therapy, gene therapy, stem cell transplantation, and pharmacological chaperone therapy are being tested in different animal models and human patients. Peroxisome proliferator-activated receptor alpha (PPARα) is a member of the nuclear hormone receptor superfamily, which along with its transcription partner retinoid X receptor alpha (RXRα) regulates the expression of their target genes. This review highlights the potential role of PPARα and RXRα in the regulation of CLN genes. Here, using the MatInspector program of the Genomatix software, we performed promoter analyses of all CLN genes and observed that most of the CLN genes harbor one or more potential binding sites for PPAR and RXR in their promoter region. We further grouped them according to a binding prediction of the transcription factors to indicate high affinity binding of PPAR to CLN2 , CLN3 , CLN4 , CLN5, CLN7 , CLN10 , CLN11 , CLN12 , and CLN14 . On the other hand, we observed high affinity binding of RXR to CLN1 , CLN3 , CLN6 , CLN7 , CLN8 , CLN10 , and CLN13 . Since PPARα and RXRα have been demonstrated to control the transcription of CLN2 gene, our current promoter analysis findings highlight a possible treatment strategy for neuronal ceroid lipofuscinoses using agonists of PPARα and RXRα.
2026-03-14 | A Flupirtine Benzyl Carbamate Improves Neurocognitive Deficits and Molecular Pathology in the Cln6nclf Mouse.
Neuronal ceroid lipofuscinosis type 6 (CLN6) is a fatal, autosomal recessive neurodegenerative disorder characterized by cognitive/motor impairment, vision loss, as well as neuronal loss and gliosis in the brain, and premature death. Onset typically occurs in childhood. No approved pharmacological treatments exist that halt or reverse disease progression. A novel flupirtine benzyl carbamate was orally administered to male and female Cln6nclf mice from 4 to 28 weeks of age to evaluate its neuroprotective and antispastic effects. Drug treatment produced significant, sex-dependent phenotypic improvements. Treated mice of both sexes exhibited reduced hindlimb spasticity, but only treated males demonstrated diminution in locomotor hyperactivity and recovery of visuospatial performance. In the brains of male and female Cln6nclf mice, flupirtine benzyl carbamate significantly decreased astrocytosis, microgliosis and mitochondrial ATP synthase subunit C (SCMAS) accumulation, increased neuronal marker expression and reduced the number of TUNEL-positive cells. The treatment failed to rescue photoreceptor loss or clear retinal SCMAS storage. These outcomes result in distinct sex-specific differences in neuronal vulnerability and drug responsiveness. Overall, these findings demonstrate that flupirtine benzyl carbamate diminishes key motor, visual and pathological deficits in CLN6 disease, highlighting its promise as a potential disease-modifying therapy for CLN6 in humans despite sex-specific differences.
2025-10-30 | Phenotype, EEG, neuroimaging and Genetic profile of Progressive Myoclonic Epilepsy in Bangladesh: An observational study
Background: Progressive myoclonic epilepsy (PME) is an epilepsy syndrome characterized by myoclonus, cognitive deficit and ataxia. Common PMEs are Unverricht–Lundborg disease, myoclonic epilepsy with ragged-red fiber (MERRF) syndrome, Lafora body disease, neuronal ceroid lipofuscinoses, and sialidases. This study was conducted to obtain baseline information on PME in terms of phenotype, EEG, MRI of the brain, and overall genetic profile. Methodology: This retrospective observational study was conducted in the Department of Pediatric Neurology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh. The duration of the study was from January 2020 to December 2023. Children diagnosed as PME on the basis of phenotype, EEG, imaging and genotype were included in this study. The genetic diagnosis was done by next-generation sequencing. Result: A total of 11 patients were analyzed in this study. The age of onset ranges from 6 months to 5 years. Consanguinity of the parents was present in 8 cases; one patient had a positive family history of a similar type of illness. The key clinical features were seizure, ataxia, neuroregression, visual impairment, dystonia etc. EEG features showed focal epileptic discharges (6), generalized discharges (5), with progressive deterioration of background in most of the cases. In MRI, 8 out of 11 patients had cerebello-cerebral atrophy. In all cases, next-generation sequencing was done; of them, three cases had KCTD7 gene mutation, three had CLN6 gene mutation causing Neuronal ceroid lipofuscinosis, another three had TPP1 gene mutation and the remaining two had MFSD8(-) gene mutation. Conclusion: This study will highlight the pattern of genotype and phenotype of children with PME in Bangladesh. J Bangladesh Coll Phys Surg 2025; 43: 269-276
Access all drug discovery articles and probability of success in trials forecasts:
Access all drug discovery articles and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for CLN6 disease.
1 orphan drug designation for CLN6 disease.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
non-replicating recombinant, self-complementary adeno-associated virus serotype 9 containing the human CLN6 gene | gene therapies | FDA | 2019-11-27 | — | The Charlotte & Gwenyth Gray Foundation to Cure Batten Disease |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.